NEW DELHI: Shares of Sun Pharma advanced 2 per cent on Wednesday as its partner Almirall received approval from European drug regulators for its psoriasis drug Tildrakizumab. The drug is used for treatment of adults with moderate-to-severe chronic plaque psoriasis, a chronic immunity disease that affects skin.
The stock rose 2.28 per cent to hit a high of Rs 657 on the BSE.
In July 2016, Sun Pharma out-licensed tildrakizumab to Almirall for development and mercialisation of the product in Europe. The rollout in Europe will start in the next few weeks, the company said in a BSE filing.